20. A replication defective recombinant adenovirus comprising a nucleic acid encoding a tumour-specific antigen.

21. The adenovirus according to claim 20, wherein the tumour is a human tumour.

22. The adenovirus according to claim 20, wherein the tumour is a melanoma.

23. The adenovirus according to claim 20, wherein the nucleic acid encodes a fragment of an antigen specific to a human melanoma, said fragment comprising the portion of the antigen presented to cytotoxic T lymphocytes in combination with MHC-I molecules.

24. The adenovirus according to claim 20, wherein the nucleic acid encodes a protein selected from the group consisting of Mage-1, Mage-3, Bage, Rage and Gage, or an antigenic peptide therefrom.

25. A replication defective recombinant adenovirus comprising a nucleic acid encoding a peptide fragment of Mage-1 or Mage-3, wherein the fragment comprises the portion of Mage-1 or Mage-3 presented to cytotoxic T lymphocytes.

26. The adenovirus according to claim 25, comprising the sequence SEQ ID No. 1.

27. The adenovirus according to claim 26, comprising the sequence lying between residues 55 and 82 of SEQ ID No. 1.

28. The adenovirus according to claim 25, comprising the sequence SEQ ID No. 2.

29. The adenovirus according to claim 20, wherein said adenovirus is selected from the group consisting of human serotype Ad2 and Ad5.

30. The adenovirus according to claim 20, wherein the adenovirus is a canine adenovirus.

31. The adenovirus according to claim 20, further comprising a deletion in the E1 region.

32. The adenovirus according to claim 31, further comprising a deletion in the E4 region.

33. The adenovirus according to claim 20, wherein the nucleic acid is inserted into the E1, E3 or E4 region of the adenovirus genome.

34. A pharmaceutical composition comprising an adenovirus according to claim 20.

35. A composition comprising cells infected with an adenovirus according to claim 20.

36. The composition according to claim 35, wherein said cells are antigen presenting cells.

37. A method of preparing cytotoxic T cells specific for a tumour antigen, the method comprising contacting a cytotoxic T cell precursor with a population of cells infected with an adenovirus according to claim 20.

38. A method of preparing cytotoxic T cells specific for a tumour antigen, the method comprising administering to a patient an adenovirus according to claim 20.

39. The method according to claim 37, wherein the tumour is a melanoma.

40. The method according to claim 38, wherein the tumour is a melanoma.

REMARKS

Applicants submit a SEQUENCE LISTING in compliance with the requirements of 37 CFR §§ 1.821-1.825. No new matter has been added.

Claims 1-19 have been cancelled and rewritten as new claims 20-40, in order to conform with US patent practice. The claims are fully supported by the claims as filed and by the specification. No new matter has been added. Early and favorable examination of this application is earnestly solicited.

Rhône-Poulenc Rorer Inc.
Legal-Patents #3C43
P.O. Box 5093
Collegeville, PA 19426-0997
Telephone: (610) 454-5643
Facsimile: (610) 454-3808

Dated: August 27, 1998

Respectfully submitted,

R. Keith Baker, Ph.D.
Agent for Applicants
Registration No. 38,799